Literature DB >> 26238689

Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Ana Barac1.   

Abstract

Entities:  

Keywords:  biomarkers; cancer treatment; cardiac imaging; cardiotoxicity; cardiovascular outcomes; cardiovascular risk models; targeted therapeutics

Mesh：

Year:  2015        PMID： 26238689      PMCID： PMC5558547          DOI： 10.2217/FCA.15.48

Source DB:  PubMed          Journal:  Future Cardiol        ISSN： 1479-6678


× No keyword cloud information.
  38 in total

1.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

2.  Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Authors:  Steven E Lipshultz; Tracie L Miller; Rebecca E Scully; Stuart R Lipsitz; Nader Rifai; Lewis B Silverman; Steven D Colan; Donna S Neuberg; Suzanne E Dahlberg; Jacqueline M Henkel; Barbara L Asselin; Uma H Athale; Luis A Clavell; Caroline Laverdière; Bruno Michon; Marshall A Schorin; Stephen E Sallan
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Circ Cardiovasc Imaging       Date:  2012-06-28       Impact factor: 7.792

4.  Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.

Authors:  Javid Moslehi; Yoji Andrew Minamishima; Jianru Shi; Donna Neuberg; David M Charytan; Robert F Padera; Sabina Signoretti; Ronglih Liao; William G Kaelin
Journal:  Circulation       Date:  2010-08-23       Impact factor: 29.690

5.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Am J Cardiol       Date:  2011-03-02       Impact factor: 2.778

6.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

8.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

Review 9.  A systematic review of dual targeting in HER2-positive breast cancer.

Authors:  Iben Kümler; Malgorzata K Tuxen; Dorte Lisbet Nielsen
Journal:  Cancer Treat Rev       Date:  2013-09-11       Impact factor: 12.111

10.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321
View more
  4 in total

1.  Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.

Authors:  Biniyam G Demissei; Yong Fan; Yiwen Qian; Henry G Cheng; Amanda M Smith; Kelsey Shimamoto; Natasha Vedage; Hari K Narayan; Marielle Scherrer-Crosbie; Christos Davatzikos; Bonnie Ky
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-03-22       Impact factor: 6.875

Review 2.  Arterial stiffness in hematologic malignancies.

Authors:  Ioana Mozos; Georgiana Borzak; Alexandru Caraba; Rodica Mihaescu
Journal:  Onco Targets Ther       Date:  2017-03-03       Impact factor: 4.147

Review 3.  Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.

Authors:  Nabeel Quryshi; Laura E Norwood Toro; Karima Ait-Aissa; Amanda Kong; Andreas M Beyer
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

4.  Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment.

Authors:  Robyn A Clark; Tania S Marin; Narelle M Berry; John J Atherton; Jonathon W Foote; Bogda Koczwara
Journal:  Cardiooncology       Date:  2017-10-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.